Mercer Global Advisors
TAK icon

Mercer Global Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Mercer Global Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Sell
167,856
-5,105
-3% -$84.5K ﹤0.01% 1177
2026
Q1 		$3.2M Sell
172,961
-2,777
-2% -$48.7K ﹤0.01% 977
2025
Q4 		$2.74M Sell
175,738
-36,858
-17% -$527K ﹤0.01% 962
2025
Q3 		$3.11M Sell
212,596
-12,638
-6% -$188K 0.01% 851
2025
Q2 		$3.48M Sell
225,234
-8,387
-4% -$124K 0.01% 686
2025
Q1 		$3.47M Buy
233,621
+59,266
+34% +$830K 0.01% 649
2024
Q4 		$2.31M Sell
174,355
-4,915
-3% -$67.5K 0.01% 775
2024
Q3 		$2.56M Buy
179,270
+9,214
+5% +$131K 0.01% 694
2024
Q2 		$2.2M Sell
170,056
-39,782
-19% -$527K 0.01% 697
2024
Q1 		$2.92M Sell
209,838
-2,933
-1% -$42.7K 0.01% 616
2023
Q4 		$3.04M Sell
212,771
-46,439
-18% -$659K 0.01% 607
2023
Q3 		$4.01M Buy
259,210
+90,669
+54% +$1.4M 0.02% 493
2023
Q2 		$2.65M Buy
168,541
+23,026
+16% +$377K 0.01% 645
2023
Q1 		$2.4M Buy
145,515
+13,749
+10% +$219K 0.01% 635
2022
Q4 		$2.06M Buy
131,766
+12,356
+10% +$173K 0.01% 680
2022
Q3 		$1.55M Buy
119,410
+2,109
+2% +$29.3K 0.01% 703
2022
Q2 		$1.65M Buy
117,301
+5,851
+5% +$83.5K 0.01% 664
2022
Q1 		$1.6M Buy
111,450
+29,570
+36% +$434K 0.01% 715
2021
Q4 		$1.12M Sell
81,880
-7,453
-8% -$105K 0.01% 835
2021
Q3 		$1.46M Buy
89,333
+9,703
+12% +$163K 0.01% 729
2021
Q2 		$1.34M Sell
79,630
-6,478
-8% -$110K 0.01% 719
2021
Q1 		$1.57M Sell
86,108
-1,366
-2% -$24.6K 0.01% 619
2020
Q4 		$1.59M Sell
87,474
-2,839
-3% -$49.8K 0.02% 479
2020
Q3 		$1.61M Buy
90,313
+3,375
+4% +$61.5K 0.02% 438
2020
Q2 		$1.56M Buy
86,938
+31,029
+55% +$557K 0.03% 375
2020
Q1 		$849K Buy
55,909
+20,004
+56% +$363K 0.02% 523
2019
Q4 		$708K Sell
35,905
-5,149
-13% -$98.5K 0.01% 613
2019
Q3 		$706K Buy
41,054
+5,882
+17% +$102K 0.02% 582
2019
Q2 		$623K Sell
35,172
-919
-3% -$16.7K 0.02% 608
2019
Q1 		$735K Buy
+36,091
New +$726K 0.03% 504

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Mercer Global Advisors's TAK Position: Q2 2026 in Review

Mercer Global Advisors reduced its Takeda Pharmaceutical (TAK) stake by 3% in Q2 2026, selling an estimated $84.5K and leaving 167,856 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

Mercer Global Advisors first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $4.01M in Q3 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Mercer Global Advisors held 167,856 shares of Takeda Pharmaceutical worth $2.69M as of Q2 2026.
  • Mercer Global Advisors sold 5,105 Takeda Pharmaceutical shares in Q2 2026, an estimated $84.5K.
  • Takeda Pharmaceutical made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1177 holding.
  • Mercer Global Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
  • Mercer Global Advisors's Takeda Pharmaceutical position peaked at $4.01M in Q3 2023.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.